Temsirolimus-based regimens were associated with significantly more grades 3 and 4 anemia, neutropenia, and thrombocytopenia; however, in general, temsirolimus alone was better tolerated than was any treatment arm that contained infα. This evidence concerns the gene IFNA17 and Decreased total neutrophil count.